Global Drug Eluting Balloon for Peripheral Artery Disease Market Strategic Research Report

Scope of the Report

The global Drug Eluting Balloon for Peripheral Artery Disease market size is predicted to grow from US$ 793 million in 2025 to US$ 1,777 million in 2032; it is expected to grow at a CAGR of 12.2% from 2026 to 2032.

Drug-eluting/drug-coated balloons (DEB/DCB) for peripheral artery disease (PAD) are angioplasty balloons coated with an antiproliferative drug (predominantly paclitaxel, with ongoing “limus” exploration) plus an excipient/carrier matrix. During inflation, they deliver mechanical lumen gain while rapidly transferring drug into the vessel wall to suppress neointimal hyperplasia and reduce restenosis and repeat interventions. Centered on a “leave nothing behind” concept, PAD-focused DCBs aim to preserve future treatment flexibility while improving durability—often used in conjunction with lesion preparation (plaque modification, scoring/cutting balloons) and intravascular imaging (e.g., IVUS) to enable more refined and repeatable peripheral vascular repair.In 2025, global Drug Eluting Balloon for Peripheral Artery Disease production reached approximately 773 k units and price is 1048 USD/Unit.The average gross profit margin of this product is 73%.

PAD care continues to shift toward minimally invasive, repair-centric strategies, and DCBs address a core clinical pain point: durable patency with reduced stent burden and fewer reinterventions. Importantly, the safety boundary has become clearer. In July 2023, the U.S. FDA updated its communication stating that the totality of available evidence does not indicate an excess late mortality risk for paclitaxel-coated devices in PAD—supporting more predictable hospital governance and pathway adoption. In parallel, leading medtech companies have highlighted drug-coated balloons as a contributor to peripheral interventions momentum in annual reporting, signaling a transition from selective use toward routine toolset adoption.

The hurdle is no longer “can you launch,” but “can you scale with reproducibility and compliant delivery.” As drug–device combination products, DCBs are highly sensitive to coating integrity, particulate control, batch-to-batch dose consistency, and shelf-life stability—where process drift can translate into outsized clinical reputation and access risk. Meanwhile, cost-containment intensifies the need to balance quality systems, supply assurance, and manufacturing efficiency. In China, drug-coated balloons have been included in national centralized procurement with publicly announced results, accelerating a more rules-based and scale-driven competitive phase. Brokerage commentary broadly notes that procurement reforms can standardize purchasing and usage and improve market order, while near-term price pressure forces value to be rebuilt through efficiency and differentiated evidence.

Demand is consolidating around repeatable techniques and bundled solutions. High recurrence and reintervention sensitivity in PAD elevate integrated optimization—lesion preparation, drug-transfer efficiency, and durable patency—driving more routine combination of DCBs with plaque-modification tools, specialty scoring/cutting balloons, and intravascular imaging (e.g., IVUS). Under tighter compliance and procurement frameworks, hospitals increasingly formalize device bundles and clinical pathways, shifting adoption from “operator preference–driven” toward “pathway management–driven” growth—where evidence communication, technique standardization, and supply reliability matter more than ever.

Upstream differentiation is ultimately an integrated “materials–coating–validation” capability rather than a simple bill of materials. Key inputs include balloon/catheter polymers and reinforcements (films, multi-durometer shafts, liners, braids/coils), drug APIs (paclitaxel or “limus” agents) with excipient/carrier systems, coating solvents and metrology consumables, lubricious/hydrophilic surface coatings, plus sterile barrier packaging and sterilization services. As regulatory scrutiny, centralized procurement fulfillment, and global compliance advance in parallel, medical-grade traceability, robust change control, and clean manufacturing at the supplier level directly shape yield, release consistency, and long-term commercial credibility.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Drug Eluting Balloon for Peripheral Artery Disease market?

What factors are driving Drug Eluting Balloon for Peripheral Artery Disease market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Drug Eluting Balloon for Peripheral Artery Disease market opportunities vary by end market size?

How does Drug Eluting Balloon for Peripheral Artery Disease break out by Type, by Application?

This report presents a comprehensive overview of the global Drug Eluting Balloon for Peripheral Artery Disease market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Iliac Artery
• Femoropopliteal
• Other

Segment by Balloon Platform Mechanics

• Semi-/Compliant
• Non-compliant
• Other

Segment by Application

• Hospitals
• Ambulatory Surgery Centers
• Catheterization Laboratories
• Others

Segment by Application

• In-Stent Restenosi
• De Novo
• Small Vessel

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Drug Eluting Balloon for Peripheral Artery Disease market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in In-Stent Restenosi, De Novo, Small Vessel evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact